Haoling Weng
Rheumatology · Los Angeles, CANPI 1679591614
Payments from drug & device makers
What this record shows
This record is dominated by consulting fees: $562,398 of the $562,398 with a category attached, or 100.0%. Every reported general payment came from a single manufacturer, Otsuka Pharmaceutical Development & Commercialization, Inc.. Among rheumatology clinicians in CA with any reported payments, this total sits in the top 5% — high for the specialty, which is a reason to read the composition above rather than the number alone.
Across 23 payments — averaging $24,452 each. Meals, travel, consulting and speaking fees, gifts and royalties reported by drug and device makers.
- Otsuka Pharmaceutical Development & Commercialization, Inc.$562K
What the payments were for
- Consulting fees$562,398100%
General payments by program year
Who reported the general payments
Companies are grouped under their corporate parent — a single manufacturer often files under several CMS reporting entities. Research and ownership payments are counted separately and are not in this table.
| Company | Payments | Total |
|---|---|---|
| Otsuka Pharmaceutical Development & Commercialization, Inc. | 23 | $562,398 |
How this compares
$562,398 in reported general payments places this provider in the 95th percentile of 808 rheumatology providers in California.
Other rheumatology in Los Angeles
- Glenn EhresmannLos Angeles$450K
- Elizabeth VolkmannLos Angeles$400K
- Daniel ArkfeldLos Angeles$378K
- Maureen McMahonLos Angeles$374K
- Leanna WiseLos Angeles$286K
- Jon GilesLos Angeles$248K
- Christina Charles-SchoemanLos Angeles$231K
- Karina Marianne TorralbaLos Angeles$142K
- Thomas RomanoLos Angeles$131K
- Gary FeldmanLos Angeles$116K
Where these figures come from
- Payments: CMS Open Payments, program years 2019–2025 (publication P06302026_06032026).
- Identity: NPPES NPI Registry, July 2026.